Rituximab: all 1,389 studies that test it

Page 4 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular LymphomaCompletedNCT01950273Phase 1Results posted
• A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)CompletedNCT01889069Phase 3Results posted
• Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT01886872Phase 3Results posted
• Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT01812005Phase 2Results posted
• Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord TransplantationCompletedNCT01810588Phase 2Results posted
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
• Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical ProstatectomyCompletedNCT01804712Early Phase 1Results posted
• A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT01796171Phase 1/2Results posted
• Renal Allograft Tolerance Through Mixed ChimerismCompletedNCT01780454Phase 1/2Results posted
• Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom MacroglobulinemiaTerminatedNCT01779167Phase 2Results posted
• Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLLCompletedNCT01754857Phase 2Results posted
• A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic PolyangiitisCompletedNCT01750697Phase 2Results posted
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732913Phase 3Results posted
• A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3aCompletedNCT01724021Phase 3Results posted
• Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus LenalidomideCompletedNCT01723839Phase 2Results posted
• Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaCompletedNCT01718691Phase 2Results posted
• Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's DiseaseCompletedNCT01702961Not applicableResults posted
• Rituximab Vasculitis Maintenance StudyCompletedNCT01697267Phase 3Results posted
• A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01691898Phase 1/2Results posted
• Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid ArthritisTerminatedNCT01682512Phase 3Results posted
• Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone LymphomaCompletedNCT01682044Phase 2Results posted
• Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in LymphomaCompletedNCT01665768Phase 2Results posted
• CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesCompletedNCT01664910Phase 1/2Results posted
• Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell LymphomaActive, not recruitingNCT01661881Phase 2Results posted
• A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell LymphomaCompletedNCT01649856Phase 3Results posted
• Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)CompletedNCT01643928Not applicableResults posted
• Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid TissueCompletedNCT01611259Phase 2Results posted
• Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous SystemTerminatedNCT01596127Phase 1/2Results posted
• Rituximab in IgG4-RD: A Phase 1-2 TrialCompletedNCT01584388Phase 1/2Results posted
• Rituximab in Pretreated Elderly or Unfit B-CLL PatientsCompletedNCT01576588Phase 2Results posted
• A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGSCompletedNCT01573533Phase 2Results posted
• Comparison of Rituximab Induction Therapy Followed by Glatiramer AcetateCompletedNCT01569451Phase 2Results posted
• Low Dose Rituximab in Thrombotic Thrombocytopenic PurpuraCompletedNCT01554514Phase 2Results posted
• Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for LymphomaCompletedNCT01538472Phase 1/2Results posted
• A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)CompletedNCT01526057Phase 2Results posted
• Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsCompletedNCT01520519Phase 2Results posted
• Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyTerminatedNCT01510184Phase 3Results posted
• Zevalin and Velcade in Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01497275Phase 2Results posted
• IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's LymphomaCompletedNCT01491841Phase 1Results posted
• Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaCompletedNCT01476787Phase 3Results posted
• Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaCompletedNCT01472562Phase 2Results posted
• Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's MacroglobulinemiaCompletedNCT01470196Phase 2Results posted
• A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous RituximabCompletedNCT01461928Phase 3Results posted
• Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell LymphomasCompletedNCT01445535Phase 1Results posted
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTerminatedNCT01434472Phase 2Results posted
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted
• GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)CompletedNCT01419665Phase 3Results posted
• A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)TerminatedNCT01390441Phase 1Results posted
• A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid ArthritisCompletedNCT01382940Phase 4Results posted
• Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)TerminatedNCT01370694Phase 1Results posted
• Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01369849Phase 1/2Results posted
• Treatment of Sickle Cell Anemia With Stem Cell TransplantTerminatedNCT01350232Not applicableResults posted
• A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid ArthritisCompletedNCT01332994Phase 3Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantCompletedNCT01321541Phase 3Results posted
• Research Study of ATG and Rituximab in Renal TransplantationTerminatedNCT01318915Early Phase 1Results posted
• A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaCompletedNCT01317901Phase 1Results posted
• Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's LymphomaTerminatedNCT01316523Phase 2Results posted
• Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT01309997Phase 2Results posted
• A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
• Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT01282476Phase 2Results posted
• Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 DiabetesCompletedNCT01280682Phase 4Results posted
• A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell DiseaseTerminatedNCT01279616Phase 2Results posted
• GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard TherapyCompletedNCT01274182Phase 1/2Results posted
• A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)CompletedNCT01272908Phase 3Results posted
• A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic StatusTerminatedNCT01271010Phase 4Results posted
• Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic LeukemiaCompletedNCT01269385Phase 1/2Results posted
• Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell TransplantationCompletedNCT01267812Phase 2Results posted
• A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic LeukemiaCompletedNCT01263704Phase 2Results posted
• Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)TerminatedNCT01253460Phase 2Results posted
• Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular LymphomaCompletedNCT01234766Phase 2Results posted
• Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell LymphomaCompletedNCT01234467Phase 2Results posted
• A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyTerminatedNCT01232556Phase 3Results posted
• Rituximab for Patients With Relapsed Acute Lymphoblastic LeukemiaTerminatedNCT01230788Not applicableResults posted
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)TerminatedNCT01212094Phase 1/2Results posted
• Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell MalignanciesCompletedNCT01206777Phase 2Results posted
• A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLTerminatedNCT01203930Phase 2Results posted
• A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's LymphomaCompletedNCT01200758Phase 3Results posted
• Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01199575Phase 2Results posted
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin LymphomaTerminatedNCT01186458Phase 2Results posted
• Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid MalignanciesCompletedNCT01181258Phase 2Results posted
• MEmbranous Nephropathy Trial Of RituximabCompletedNCT01180036Phase 2/3Results posted
• Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney TransplantationCompletedNCT01178216Phase 1/2Results posted
• Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLLTerminatedNCT01173679Phase 2Results posted
• Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin LymphomaCompletedNCT01165112Phase 1/2Results posted
• Rituximab to Prevent Recurrence of ProteinuriaTerminatedNCT01164098Phase 3Results posted
• Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)CompletedNCT01161628Phase 2Results posted
• A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular LymphomasCompletedNCT01153971Phase 2Results posted
• Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedNCT01145495Phase 2Results posted
• A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.TerminatedNCT01144403Phase 2Results posted
• A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)CompletedNCT01144364Phase 3Results posted
• CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)CompletedNCT01134575Phase 2Results posted
• R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical TrialCompletedNCT01133158Phase 2Results posted
• SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa TherapyCompletedNCT01126541Phase 3Results posted
• Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLLCompletedNCT01125176Phase 2Results posted
• Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01118845Phase 2Results posted
• Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2Results posted
• Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem CellsCompletedNCT01097057Phase 2Results posted
• Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT01096992Phase 1/2Results posted
• Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)CompletedNCT01086540Phase 2Results posted

← Rituximab overview